Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Debate over insurer costs and access as Montana committee weighs coverage mandate for GLP‑1 drugs
Summary
Sen. Ellie Boldman told the committee SB 417 would require private insurers to cover GLP‑1 drugs when a physician prescribes them for approved conditions; physicians and patient groups supported coverage while insurers warned of large fiscal impacts and urged careful drafting or limits tied to medical necessity.
Senator Ellie Boldman opened Senate Bill 417 to require insurance coverage for GLP‑1 medications when prescribed for FDA‑approved indications such as type‑2 diabetes and obesity with associated diagnoses. Boldman said the drugs—commonly known by brand names such as Wegovy and Ozempic—deliver clinical benefits for glycemic control and cardiovascular risk and should be covered when a physician prescribes them.
Physicians and advocates testified in favor of the measure, emphasizing clinical benefit and patient access. Opposing testimony came…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
